Please use this identifier to cite or link to this item:
Title: Costs and healthcare utilisation of patients with heart failure in Spain
Author: Escobar, Carlos
Varela, Luis
Palacios, Beatriz
Capel, Margarita
Sicras, Antoni
Sicras, Aram
Hormigo, Antonio
Alcázar, Roberto
Manito Lorite, Nicolás
Botana, Manuel
Keywords: Insuficiència cardíaca
Hypoglucemic agents
Heart failure
Issue Date: 20-Oct-2020
Publisher: BioMed Central
Abstract: Background: Increasing the knowledge about heart failure (HF) costs and their determinants is important to ascertain how HF management can be optimized, leading to a significant decrease of HF costs. This study evaluated the cumulative costs and healthcare utilisation in HF patients in Spain. Methods: Observational, retrospective, population-based study using BIG-PAC database, which included data from specialized and primary care of people ≥18 years, from seven autonomous communities in Spain, who received care for HF between 2015 and 2019. The healthcare and medication costs were summarized on a yearly basis starting from the index date (1st January 2015), and then cumulatively until 2019. Results: We identified 17,163 patients with HF (year 2015: mean age 77.3 ± 11.8 years, 53.5% men, 51.7% systolic HF, 43.6% on NYHA functional class II). During the 2015–2019 period, total HF associated costs reached 15,373 Euros per person, being cardiovascular disease hospitalizations the most important determinant (75.8%), particularly HF hospitalizations (51.0%). Total medication cost accounted for 7.0% of the total cost. During this period, there was a progressive decrease of cardiovascular disease hospital costs per year (from 2834 Euros in 2015 to 2146 Euros in 2019, P < 0.001), as well as cardiovascular and diabetic medication costs. Conclusions: During the 2015–2019 period, costs of HF patients in Spain were substantial, being HF hospitalizations the most important determinant. Medication costs represented only a small proportion of total costs. Improving HF management, particularly through the use of drugs that reduce HF hospitalization may be helpful to reduce HF burden.
Note: Reproducció del document publicat a:
It is part of: BMC Health Services Research, 2020, vol. 20
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
EscobarC.pdf958.96 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons